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Abstract Purpose: To describe
temporal trends in the epidemiology,
clinical management and outcome of
candidemia in intensive care unit
(ICU) patients. Methods: This study
was a retrospective analysis of 1,392
episodes of candidemia in 647 adult
ICU patients from 22 Brazilian hos-
pitals. The characteristics of
candidemia in these ICU patients
were compared in two periods
(2003–2007, period 1; 2008–2012,
period 2), and the predictors of
30-day mortality were assessed.
Results: The proportion of patients
who developed candidemia while in
the ICU increased from 44 % in
period 1 to 50.9 % in period 2
(p = 0.01). Prior exposure to fluco-
nazole before candidemia (22.3 vs.
11.6 %, p \ 0.001) and fungemia due
to Candida glabrata (13.1 vs. 7.8 %,
p = 0.03) were more frequent in
period 2, as was the proportion of
patients receiving an echinocandin as
primary therapy (18.0 vs. 5.9 %,
p \ 0.001). The 30-day mortality rate
decreased from 76.4 % in period 1 to
60.8 % in period 2 (p \ 0.001). Pre-
dictors of 30-day mortality by
multivariate analysis were older age,
period 1, treatment with corticoste-
roids and higher APACHE II score,
while treatment with an echinocandin
were associated with a higher proba-
bility of survival. Conclusions: We
found a clear change in the epidemi-
ology and clinical management of
candidemia in ICU patients over the
9-year period of the study. The use of
echinocandins as primary therapy for
candidemia appears to be associated
with better outcomes.
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Introduction
Despite the best efforts of the medical community, the
morbidity and mortality associated with candidemia
remains elevated, with crude mortality rates of C40 %
[1–3]. In addition, population-based studies conducted in
the USA and Europe suggest that the incidence of can-
didemia has increased during the last decade [4–6].
Patients admitted to intensive care units (ICUs) are at
high risk of developing candidemia, with recent
Intensive Care Med (2014) 40:1489–1498
DOI 10.1007/s00134-014-3400-y ORIGINAL
multicenter studies reporting that 30–40 % of candidemic
patients were in ICUs at the time of the diagnosis. Delays
in initiating antifungal therapy may increase mortality
rates in patients with candidemia [7, 8]. Consequently,
serious attempts have been directed to validating predic-
tive guidelines based on risk factors and/or the presence
of fungal biomarkers in order to assist clinicians in their
decision to provide early antifungal therapy to patients at
high risk [9–12].
In Latin America, overall mortality rates of patients
with candidemia are usually higher than those observed in
the Northern Hemisphere [13–15]. However, it should be
noted that data on the epidemiology and prognostic fac-
tors associated with candidemia in patients admitted to
ICUs in Latin America are scarce. Therefore, the main
objective of this study was to evaluate historical trends in
the epidemiology and clinical management of patients
admitted to ICUs in tertiary care hospitals in Brazil, as
well as to identify the prognostic factors of candidemia.
Patients and methods
Patient selection and data collection
This is a retrospective analysis of a collection of candi-
demia cases created by merging the databases of five
prospective laboratory-based surveillance cohorts con-
ducted in 22 tertiary care medical centers in Brazil
between March 2003 and February 2012. Only tertiary
care hospitals providing medical care in most medical
specialties participated in these five studies, and they can
be categorized as public hospitals (n = 13), which pro-
vide medical assistance to low-income patients, and
private hospitals (n = 9), which are for-profit medical
institutions that provide care mostly to patients covered
by private insurance plans. These hospitals are represen-
tative of public and private reference medical centers
located in 12 large cities in Brazil. In the first two cohorts,
only patients from public hospitals were enrolled, while in
the latter three cohort studies, the patients were from a
mixture of public and private hospitals.
An investigator at each medical center was assigned
the specific task of contacting the microbiology laboratory
of the hospital on a weekly basis in order to collect
clinical and epidemiological data of all incident cases of
candidemia. This investigator was trained to record such
data on a standard case report form using a dictionary of
terms that included all definitions of underlying condi-
tions and medical exposures collected during the study.
The case report form, dictionary of terms and strategy for
data collection were the same in all five surveillance
studies. Patients were followed up to 30 days after the
incident candidemia or death. A case of candidemia was
defined as the incident isolation of Candida spp. from a
blood culture. The date of the incident candidemia was
defined as the date of the collection of the blood culture
that became positive for Candida species. Candidemia
occurring [30 days after the incident isolation was
defined as a new case. Fever was defined as an axillary
temperature of C37.8 C and neutropenia as an absolute
neutrophil count of\500/mm3. Cardiac and lung diseases
were considered if the patient presented any cardiac or
lung condition requiring active treatment. Such conditions
included (but were not restricted to) congestive heart
failure, coronary arterial disease, hypertension and car-
diac arrhythmias (cardiac diseases), as well as chronic
obstructive pulmonary disease, asthma, emphysema,
bronchiectasis or chronic pneumonia or interstitial disease
of any etiology (lung disease). Renal failure was defined
as any documented serum creatinine value of [1.5 g/dL.
With the exception of invasive medical procedures
and antibiotic use, we considered all these manifestations
documented up to 30 days before the date of the incident
candidemia as conditions associated with candidemia.
Data on central venous catheters, dialysis and antibiotic
use were captured up to 15 days before the onset of
candidemia. Data on surgery requiring general anesthesia
was captured up to 3 months before candidemia. All
medical records were reviewed and monitored by a cen-
tral data collection system for the analysis of
completeness and consistency. In cases of uncompleted or
inconsistent clinical forms, queries were generated and
sent back to the investigators for corrections or
completion.
Yeast identification
All Candida bloodstream isolates were sent to a central
laboratory (Special Mycology Laboratory, Escola Paulista
de Medicina, UNIFESP) for further species identification
based on the micromorphologic characteristics of the
colonies and biochemical tests (ID 32C system; Bio-
Me´rieux, Marcy l’Etoile, France).
Data analysis
For this analysis we excluded patients aged \18 years.
We compared candidemia occurring in ICU patients
versus non-ICU patients in terms of baseline character-
istics, clinical manifestations, species distribution,
treatment and outcome. In addition, we arbitrarily defined
two 5-year periods (2003–2007, period 1; 2008–2012,
period 2) and compared the epidemiological characteris-
tics of ICU patients admitted in these two periods.
Additional analyses included comparison of the epide-
miology of candidemia in ICU patients from public versus
private institutions. Finally, prognostic factors for ICU
patients with candidemia were identified by comparing
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patients who died versus those who survived for 30 days
after the candidemia episode.
Categorical variables were analyzed using chi-square
or Fisher’s exact tests, as appropriate, and continuous
variables were compared using the Wilcoxon test. A
p value of \0.05 was considered to be statistically sig-
nificant. Variables significant at p \ 0.1 by univariate
analysis were included in a multivariate model (backward
and forward). Statistical analyses were performed using
SPSS version 15.0 (SPSS, Inc., Chicago, IL).
Results
A total of 1,392 episodes of candidemia were collected
for analysis. The median age of the patient cohort was 62
(range 18–97) years, and 718 were males. C. albicans was
the leading etiologic agent of candidemia (42 %), fol-
lowed by C. tropicalis (20 %), C. parapsilosis (19 %) and
C. glabrata (9 %). The 30-day crude mortality rate was
62.4 %.
In 647 episodes (46.5 %) the patient was in an ICU at
the time candidemia was diagnosed. Comparison between
these patients and those who were not in an ICU is shown
in Table 1 where it can be seen that ICU patients were
older (median of 66 vs. 58 years, p \ 0.001) and more
likely to present comorbidities such as renal failure and
neurologic, cardiac or lung disease. Likewise, ICU
patients were more likely to have been exposed to surgery,
dialysis, mechanical ventilation, central venous catheteri-
zation and antibiotics. However, non-ICU patients with
candidemia were more likely to have cancer (especially
hematologic malignancies), organ transplantation and
auto-immune diseases. Non-ICU patients were also more
likely to have neutropenia and to have received anticancer
chemotherapy and immunosuppressive drugs. The 30-day
crude mortality rate was 70.3 % in ICU patients and
52.6 % in non-ICU patients (p \ 0.001). In terms of
species distribution, the only significant difference was a
lower proportion of C. parapsilosis among ICU patients
(17.2 vs. 21.7 %, p = 0.03). Of note, both the proportion
of C. glabrata candidemia and prior exposure to azoles
were similar among ICU and non-ICU patients.
The proportion of patients who developed candidemia
while in the ICU increased from 44 % in period 1 to
50.9 % in period 2 (p = 0.01). Table 2 shows the com-
parisons of episodes in the two periods. As expected, the
proportion of patients in private hospitals was higher in
period 2, as was the proportion of patients with liver or
neurologic diseases. Prior exposure to fluconazole (22.3
vs. 11.6 %, p \ 0.001) and candidemia due to C. glabrata
(13.1 vs. 7.8 %, p = 0.03) were also more frequent in
period 2. Of note, the increase in the proportion of
C. glabrata over the entire study period was mostly dri-
ven by a change in the proportion of public institutions
[5.1 (period 1) vs. 10.5 % (period 2), p = 0.07] compared
to private centers [11.1 (period 1) vs. 15.1 % (period 2),
p = 0.29].
Antifungal treatment was given to 72.7 % of patients
in period 1 and 77.3 % in period 2 (p = 0.19). During the
study period the antifungal drugs prescribed for the pri-
mary treatment of candidemia changed, with a decrease in
the use of deoxycholate amphotericin B (27.8 vs. 13.4 %,
p \ 0.001) and an increase in the use of echinocandins
(5.9 vs. 18.0 %, p \ 0.001). The use of lipid formulations
of amphotericin B also increased from period 1 to period
2 (3.1 vs. 6.2 %, p = 0.11), but the difference was not
statistically significant. Of interest, the 30-day crude
mortality rate decreased from 76.4 % in period 1 to
60.8 % in period 2 (p \ 0.001).
The main characteristics of candidemic patients
according to admission to ICUs of public or private hos-
pitals are shown in Table 3. Patients in public hospitals
were significantly younger, and a higher proportion had
autoimmune and lung diseases; in private hospitals, a
higher number of patients had neutropenia and received
cancer chemotherapy. In terms of species distribution, C.
albicans was more frequently isolated in public institu-
tions (48.6 vs. 39.6 %, p = 0.02), whereas C. glabrata
(12.9 vs. 6.9 %, p = 0.01) and C. krusei (3.7 vs. 1.2 %,
p = 0.05) were more prone to be isolated in private
medical centers. In terms of antifungal therapy, echino-
candins (2.9 vs. 18.5 %, p \ 0.001) and lipid formulations
of amphotericin B (1.3 vs. 7.4 %, p = 0.001) were more
likely to be used for the treatment of candidemia in private
institutions, whereas deoxycholate amphotericin B was
more frequently used in the public institutions (31.8 vs.
12.3 %, p \ 0.001). The 30-day crude mortality rate was
75.3 % in the public hospitals and 65.3 % in private
institutions (p = 0.006).
As shown in Table 4, the following variables were
associated with higher 30-day mortality by univariate
analysis: older age, period 1, public hospital, higher acute
physiologic and chronic health evaluation (APACHE) II
score, cancer, lung disease, renal failure, dialysis,
mechanical ventilation, receipt of corticosteroids, no
treatment for candidemia and treatment with deoxycho-
late amphotericin B. Infection due to C. parapsilosis and
treatment with an echinocandin were associated with
lower mortality.
By multivariate analysis (Table 5), older age [odds
ratio (OR) 1.03, 95 % confidence interval (CI)
1.01–1.05], period 1 (OR 2.49, 95 % CI 1.22–5.08),
corticosteroid treatment (OR 4.00, 95 % CI 1.98–8.13)
and higher APACHE II score (OR 1.05, 95 % CI
1.01–1.09) were associated with an increased risk of
death. By contrast, treatment with an echinocandin (OR
0.20, 95 % CI 0.07–0.58) was associated with a higher
probability of survival. Prognostic factors were also
evaluated in the 745 patients who were not in an ICU
(Electronic Supplementary Material Table A). Among
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these patients, the variables associated with 30-day mor-
tality were period 1(OR 2.67, 95 % CI 1.33–5.33,
p = 0.005), mechanical ventilation (OR 3.87, 95 % CI
1.46–10.31, p = 0.007) and antibiotic treatment (OR
5.87, 95 % CI 1.71–18.18, p = 0.004).
Discussion
In this study we observed that while the 30-day crude
mortality rate of patients with candidemia admitted to an
ICU was very high, it decreased from 76.4 % in period 1
(2003–2007) to 60.8 % in period 2 (2008–2012). We also
observed that among the predictors of outcome identified
by multivariate analysis, the use of an echinocandin as
primary therapy for candidemia was associated with a
better outcome and that echinocandins were increasingly
being used as primary therapy for candidemia in period 2.
Critically ill patients still represent a large proportion
of patients who develop candidemia in tertiary care hos-
pitals. In the present study, the proportion of candidemic
patients in an ICU was 46.5 % over the entire study
period and increased in period 2. As expected, compared
to non-ICU patients, patients already admitted to an ICU
when candidemia was diagnosed were more likely to have
Table 1 Characteristics of patients admitted to an intensive care unit (ICU) versus those of patients not in an ICU at the time of
candidemia diagnosis
Variable In the ICU (N = 647) Outside the ICU (N = 745) p
Gender (N, male:female) 328:319 390:355 0.54
Age (years) 66 (18–97) 58 (18–97) \0.001
Time (days) from admission to candidemia diagnosis 20 (0–188) 20 (0–159) 0.83
Cancer 174 (26.9) 283 (38.0) \0.001
Hematologic 29 (4.5) 95 (12.8) \0.001
Solid tumor 145 (22.4) 188 (25.2) 0.22
Diabetes 154 (24.4) 170 (22.8) 0.48
Renal failure 262 (40.5) 217 (29.1) \0.001
Chronic renal failure 81 (12.5) 113 (15.2) 0.15
Dialysis 183 (28.3) 118 (15.8) \0.001
Liver disease 74 (11.4) 91 (12.2) 0.65
Auto-immune disease 28 (4.3) 52 (7.0) 0.03
Neurologic disease 160 (24.7) 141 (18.9) 0.009
Transplant 3 (0.5) 27 (3.6) \0.001
Cardiac disease 227 (35.1) 163 (21.9) \0.001
Lung disease 185 (28.6) 120 (16.1) \0.001
Surgery 336 (51.9) 328 (44.0) 0.003
Abdominal surgery 194 (30.0) 189 (25.4) 0.05
Mechanical ventilation 480 (74.2) 120 (16.1) \0.001
Total parenteral nutrition 140 (21.6) 157 (21.1) 0.80
Central venous catheter 605 (93.5) 591 (79.3) \0.001
Neutropenia 16 (2.5) 51 (6.8) \0.001
Prior drug/treatment exposure
Antibiotics 622 (96.1) 653 (87.7) \0.001
Corticosteroids 338 (52.2) 223 (29.9) \0.001
Other immunosuppressive drugs 38 (5.9) 67 (9.0) 0.03
Chemotherapy 22 (3.4) 76 (10.2) \0.001
Fluconazole prior to candidemia 102 (15.8) 108 (14.5) 0.51
Candida spp.
C. albicans 285 (44.0) 300 (40.3) 0.15
C. parapsilosis 111 (17.2) 162 (21.7) 0.03
C. tropicalis 141 (21.8) 140 (18.8) 0.16
C. glabrata 64 (9.9) 68 (9.1) 0.63
C. krusei 16 (2.5) 21 (2.8) 0.69
C. guilliermondii 12 (1.9) 22 (3.0) 0.19
Treatment received 482 (74.5) 577 (77.4) 0.20
Fluconazole 295/482 (61.2) 395/577 (68.5) 0.01
Deoxycholate AMB 106/482 (22.0) 106/577 (18.4) 0.14
Lipid AMB 21/482 (4.4) 8/577 (1.4) 0.003
Echinocandins 52/482 (10.8) 33/577 (5.7) 0.002
30-day crude mortality 450/640 (70.3)a 389/740 (52.6)b \0.001
AMB, Amphotericin B
Data are presented as a number with the percentage given in
parenthesis, or as the median with the range given in parenthesis,
unless specified otherwise
a Status on day 30 was not known in 7 patients
b Status on day 30 was not known in 5 patients
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received antibiotics and invasive medical procedures,
while cancer and transplantation were more frequent in
non-ICU patients.
An interesting finding of our study relates to changes
in the epidemiology and clinical management of candi-
demia over the 9-year period covered by this study. In
parallel with the observed increase in the proportion of
candidemic patients who had been exposed to fluconazole
prior to being diagnosed with candidemia, we found a
substantial rise in the proportion of candidemia due to
C. glabrata. The association between previous exposure
to fluconazole and candidemia due to C. glabrata has
been extensively reported [16–19]. While epidemiologic
studies of candidemia in Latin America still show a rel-
atively low proportion of candidemia caused by species
that exhibit a lower susceptibility to fluconazole [14], the
emergence of C. glabrata has been documented in other
studies from the region [20–22].
A dramatic finding in our study was the unacceptably
high 30-day crude mortality of candidemic ICU patients,
both in public and private hospitals. Indeed, two large
studies published in the USA reported a decrease in the
Table 2 Characteristics of ICU patients with candidemia in the two study periods, 2003–2007 (period 1) and 2008–2012 (period 2)
Variable Period 1 (N = 396) Period 2 (N = 251) p
Gender (N, male:female) 206:190 122:129 0.40
Age (years) 67 (18–97) 63 (19–97) 0.67
Time (days) from admission to candidemia diagnosis 21 (0–142) 16 (0–188) 0.01
Private hospital 340 (37.8) 242 (49.3) \0.001
APACHE II score, median (range)a 27 (0–46) 22 (3–42) 0.08
Cancer 102 (25.8) 72 (28.7) 0.41
Hematologic 14 (3.5) 15 (6.0) 0.14
Solid tumor 88 (22.2) 57 (22.7) 0.88
Diabetes 96 (24.2) 62 (24.7) 0.89
Renal failure 162 (40.9) 100 (39.8) 0.79
Chronic renal failure 57 (14.4) 24 (9.6) 0.07
Dialysis 112 (28.3) 71 (28.3) 1.00
Liver disease 32 (8.1) 42 (16.7) 0.001
Auto-immune disease 18 (4.5) 10 (4.0) 0.73
Neurologic disease 83 (21.0) 77 (30.7) 0.005
Transplant 2 (0.5) 1 (0.4) 1.00
Cardiac disease 142 (35.9) 85 (33.9) 0.60
Lung disease 106 (26.8) 79 (31.5) 0.20
Surgery 205 (51.8) 131 (52.2) 0.92
Abdominal surgery 129 (32.6) 66 (25.9) 0.07
Mechanical ventilation 296 (74.7) 184 (73.3) 0.68
Total parenteral nutrition 83 (21.0) 57 (22.7) 0.60
Central venous catheter 364 (91.9) 241 (96.0) 0.04
Neutropenia 9 (2.3) 7 (2.8) 0.68
Prior drug/treatment exposure
Antibiotics 377 (95.2) 245 (97.6) 0.12
Corticosteroids 202 (51.0) 136 (54.2) 0.43
Other immunosuppressive drugs 23 (5.8) 15 (6.0) 0.93
Chemotherapy 7 (1.8) 15 (6.0) 0.004
Fluconazole prior to candidemia 46 (11.6) 56 (22.3) \0.001
Candida spp.
C. albicans 177 (44.7) 108 (43.0) 0.68
C. parapsilosis 72 (18.2) 39 (15.5) 0.38
C. tropicalis 90 (22.7) 51 (20.3) 0.47
C. glabrata 31 (7.8) 33 (13.1) 0.03
C. krusei 5 (1.3) 11 (4.4) 0.01
C. guilliermondii 9 (2.3) 3 (1.2) 0.38
Treatment received 288 (72.7) 194 (77.3) 0.19
Fluconazole 174/288 (60.4) 121/194 (62.4) 0.67
Deoxycholate AMBb 80/288 (27.8) 26/194 (13.4) \0.001
Lipid AMBb 9/288 (3.1) 12/194 (6.2) 0.11
Echinocandin 17/288 (5.9) 35/194 (18.0) \0.001
30-day crude mortality 298/390 (76.4)c 152/250 (60.8)d \0.001
Data are presented as a number with the percentage given in
parenthesis, or as the median with the range given in parenthesis,
unless specified otherwise
a APACHE, Acute physiologic and chronic health evalua-
tion (Data available for 261 patients only)
b AMB, amphotericin B
c Status on day 30 was not known in 6 patients
d Status on day 30 was not known in 1 patient
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mortality rate of patients with candidemia during the last
10 years [5, 18]. The crude mortality rate in the EPIC
study evaluating candidemia in ICUs was 42 % [23], and
two European studies reported 30-day mortality of 47 %
[24, 25]. The high mortality rate observed in our series
may be multifactorial and include poor general clinical
conditions of sick patients (especially from public hos-
pitals), delays in making a diagnosis and the choice of
treatment.
Interestingly, we observed a significant decrease in the
crude mortality rate of patients with candidemia in the
second period of the analysis. When we compared the
clinical characteristics of patients from both periods, we
found that age distribution and underlying conditions
were similar, with the exception of neurologic and liver
diseases, which were more common in period 2. In
addition, the APACHE II score was slightly lower in
period 2, although the difference was not statistically
significant. We do not believe that these differences
explain the significant reduction in the death rate in period
2—rather, important differences in the clinical manage-
ment of candidemia did occur in period 2. Patients from
the latter period were more likely to have been treated
with echinocandins and less likely to have received
deoxycholate amphotericin B. Various studies, including
a randomized clinical trial [26] and a patient-level pooled
analysis of randomized clinical trials [27], have shown
that the outcome of candidemia is better when an
Table 3 Characteristics of patients with candidemia according to admission to ICUs of public and private hospitals
Variable Public (N = 321) Private (N = 326) p
Gender (N, male:female) 169:152 159:167 0.32
Age (years) 60 (18–97) 64 (18–97) \0.001
Time (days) from admission to candidemia 20 (0–188) 19 (0–159) 0.62
Cancer 79 (24.6) 95 (29.1) 0.19
Hematologic 10 (3.1) 19 (5.8) 0.09
Solid tumor 69 (21.5) 76 (23.3) 0.58
Diabetes 69 (21.5) 89 (27.3) 0.09
Renal failure 126 (39.3) 136 (41.7) 0.52
Chronic renal failure 45 (14.0) 36 (11.0) 0.25
Dialysis 88 (27.4) 95 (29.1) 0.63
Liver disease 34 (10.6) 40 (12.3) 0.50
Auto-immune disease 20 (6.2) 8 (2.5) 0.02
Neurologic disease 75 (23.4) 85 (25.1) 0.42
Transplant 1 (0.3) 2 (0.6) 1.00
Cardiac disease 113 (35.2) 114 (35.0) 0.95
Lung disease 106 (33.0) 79 (24.2) 0.01
Surgery 164 (51.1) 172 (52.8) 0.67
Abdominal surgery 96 (29.9) 98 (30.1) 0.97
Mechanical ventilation 247 (76.9) 233 (71.5) 0.11
Total parenteral nutrition 68 (21.2) 72 (22.1) 0.78
Central venous catheter 297 (92.5) 308 (94.5) 0.31
Neutropenia 3 (0.9) 13 (4.0) 0.01
Prior drug/treatment exposure
Antibiotics 310 (96.6) 312 (95.7) 0.57
Corticosteroids 173 (53.9) 165 (50.6) 0.40
Immunosuppressive drugs 18 (5.6) 20 (6.1) 0.77
Chemotherapy 4 (1.2) 18 (5.5) 0.003
Fluconazole prior to candidemia 43 (13.4) 59 (18.1) 0.10
Candida spp.
C. albicans 156 (48.6) 129 (39.6) 0.02
C. parapsilosis 61 (19.0) 50 (15.3) 0.22
C. tropicalis 64 (19.9) 77 (23.6) 0.26
C. glabrata 22 (6.9) 42 (12.9) 0.01
C. krusei 4 (1.2) 12 (3.7) 0.05
C. guilliermondii 7 (2.2) 5 (1.5) 0.54
Treatment received 239 (74.5) 243 (74.5) 0.98
Fluconazole 147/239 (61.5) 148/243 (60.9) 0.89
Deoxycholate AMB 76/239 (31.8) 30/243 (12.3) \0.001
Lipid AMB 3/239 (1.3) 18/243 (7.4) 0.001
Echinocandin 7/239 (2.9) 45/243 (18.5) \0.001
30-day crude mortality 241/320 (75.3)a 209/320 (65.3)b 0.006
Data are presented as a number with the percentage given in
parenthesis, or as the median with the range given in parenthesis,
unless specified otherwise
a Status on day 30 was not known in 1 patient
b Status on day 30 was not known in 6 patients
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echinocandin is used as primary therapy. Therefore, it is
reasonable to assume that the observed decrease in 30-day
crude mortality in period 2 may have been, at least in part,
due to the increase in the use of echinocandins as primary
therapy, especially since treatment with an echinocandin
was an independent predictor of better outcome by the
multivariate analysis.
As already reported in other studies, older age, treat-
ment with corticosteroids and higher APACHE II score
were associated with an increased risk of death [2, 25, 28–
31]. In addition, period 1 was also associated with a higher
risk of death. It is possible that differences in factors
related to patient care not captured in the present study
contributed to the better survival observed in period 2.
Our study has a number of limitations related to its
retrospective nature. For example, we did not have data to
calculate incidence rates of candidemia in and outside the
ICU. Likewise, data on trends in susceptibility of Candida
bloodstream isolates could not be provided because of
changing standards in reading the test over time. Never-
theless, according to the standards in each period,
fluconazole resistance occurred in \10 % of isolates and
was almost exclusively limited to C. glabrata and C. kru-
sei (data not shown). Another limitation of our study is that
Table 4 Factors associated with 30-day mortality among 640 ICU patientsa with candidemia by univariate analysis
Variable Alive (N = 190) Dead (N = 450) p value
Gender (N, male:female) 94:96 233:217 0.59
Age (years) 60 (19–97) 68 (18–97) \0.001
Time (days) from admission to candidemia 17 (0–151) 20.5 (0–188) 0.10
Period 2 (2008–2012) 98 (51.6) 152 (33.8) \0.001
Private hospital 111 (58.4) 79 (41.6) 0.006
APACHE II scoreb 19 (3–37) 27 (0–46) \0.001
Cancer 31 (16.3) 140 (31.1) \0.001
Hematologic 7 (3.7) 21 (4.7) 0.58
Solid tumor 24 (12.6) 119 (26.4) \0.001
Cardiac disease 62 (32.6) 161 (35.8) 0.44
Lung disease 42 (22.1) 141 (31.3) 0.02
Diabetes 49 (25.8) 107 (23.8) 0.59
Renal failure 61 (32.1) 199 (44.2) 0.004
Chronic renal failure 20 (10.5) 60 (13.3) 0.33
Dialysis 32 (16.8) 149 (33.1) \0.001
Liver disease 13 (8.9) 56 (12.4) 0.20
Auto-immune disease 4 (2.1) 24 (5.3) 0.07
Neurologic disease 53 (27.9) 104 (23.1) 0.20
Transplant 0 3 (0.7) 0.56
Surgery 108 (56.8) 226 (50.2) 0.13
Abdominal surgery 54 (28.4) 139 (30.9) 0.53
Mechanical ventilation 117 (61.6) 378 (79.6) \0.001
Total parenteral nutrition 42 (22.1) 97 (21.6) 0.88
Central venous catheter 176 (92.6) 422 (93.8) 0.59
Neutropenia 2 (1.1) 14 (3.1) 0.17
Prior drug/treatment exposure
Antibiotics 181 (95.3) 436 (96.9) 0.31
Corticosteroids 74 (38.9) 259 (57.6) \0.001
Other immunosuppressive drugs 9 (4.7) 29 (6.4) 0.40
Chemotherapy 6 (3.2) 16 (3.6) 0.80
Fluconazole prior to candidemia 36 (18.9) 65 (14.4) 0.15
Candida spp.
C. albicans 73 (38.4) 210 (46.7) 0.055
C. parapsilosis 43 (22.6) 67 (14.9) 0.02
C. tropicalis 39 (20.5) 99 (22.0) 0.68
C. glabrata 23 (12.1) 40 (8.9) 0.21
C. krusei 5 (2.6) 11 (2.4) 1.00
C. guilliermondii 2 (1.1) 10 (2.2) 0.52
Treatment received 176 (92.6) 301 (66.9) \0.001
Fluconazole 106/176 (60.2) 185/301 (61.5) 0.79
Deoxycholate AMB 27/176 (15.3) 78/301 (25.9) 0.007
Lipid AMB 8/176 (4.5) 13/301 (4.3) 0.91
Echinocandin 31/176 (17.6) 21/301 (7.0) \0.001
Time (days) from candidemia to treatment 2 (0–11) 2 (0–18) 0.12
Data are presented as a number with the percentage given in
parenthesis, or as the median with the range given in parenthesis,
unless specified otherwise
a Status on day 30 was not known in 7 patients
b Data available for 258 patients only
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the APACHE II score was not available in a significant
proportion of cases, limiting the number of patients ana-
lyzed in the multivariate analysis. Likewise, since the time
of central venous catheter removal is critical to an analysis
of its impact on the outcome [32], we were not able to do
such an analysis because the date of catheter removal was
not available for the majority of patients.
In conclusion, we found a clear change in the epide-
miology and clinical management of candidemia in ICU
patients during the 9-year period of this study. The
incorporation of echinocandins as primary therapy for
candidemia in critically ill patients seems to be associated
with better outcomes.
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